Bavarian Nordic Reports Interim Data From Phase I/II Studies With Breast Cancer Vaccine

Bavarian Nordic Reports Interim Data From Phase I/II Studies With Breast Cancer Vaccine

KVISTGÅRD, Denmark, June 19 /PRNewswire/ -- Bavarian Nordic's cancer research unit, BN ImmunoTherapeutics, has completed an interim analysis of its first two clinical studies with MVA-BN®-HER2, a cancer vaccine immunotherapy for breast cancer patients. 
The first study, performed in the US, is evaluating MVA-BN®-HER2 treatment following chemotherapy and Herceptin® treatment. In the second study, performed in Serbia and Poland, MVA-BN®-HER2 is being evaluated following only chemotherapy or in combination with single-agent taxane chemotherapy. Both studies evaluate treatment of metastatic breast cancer patients, whose tumors overexpress HER2. Patients are vaccinated 3 times, at 3 week intervals, with the MVA-BN® viral vector which has been engineered to express the extracellular fragment of human HER2.

With 27 out of 30 patients vaccinated, enrolment in the studies is nearly completed. No drug-related severe adverse events have been reported thus far. The vaccine has been shown to be well tolerated and immunogenic.

Immune evaluation of samples from 18 patients treated with MVA-BN®-HER2 revealed that 12 patients developed an immune response (humoral and/or cellular response).

These preliminary data show that MVA-BN®-based, HER2 directed vaccination is a biologically active treatment for patients with HER2 positive breast cancer. The final study data are expected around the turn of the year 2008/2009.

Anders Hedegaard, President & CEO of Bavarian Nordic, commented: "I am pleased that we once again can confirm the unique safety profile of MVA-BN® and that we have been able to show immunogenicity in this patient group suffering from this severe disease."

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN® is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE®.

Bavarian Nordic is listed on the OMX Nordic Exchange Copenhagen under the symbol BAVA.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.